The DOI matches its Crossref record; 83 of the 83 references it cites were found in a registry or an index.
ErbB2 Potentiates Breast Tumor Proliferation through Modulation of p27 Kip1 -Cdk2 Complex Formation: Receptor Overexpression Does Not Determine Growth Dependency
Open accessAbstract
Overexpression of the ErbB2 receptor, a major component of the ErbB receptor signaling network, contributes to the development of a number of human cancers. ErbB2 presents itself, therefore, as a target for antibody-mediated therapies. In this respect, anti-ErbB2 monoclonal antibody 4D5 specifically inhibits the growth of tumor cells overexpressing ErbB2. We have analyzed the effect of 4D5-mediated ErbB2 inhibition on the cell cycle of the breast tumor cell line BT474. 4D5 treatment of BT474 cells resulted in a G(1) arrest, preceded by rapid dephosphorylation of ErbB2, inhibition of cytoplasmic signal transduction pathways, accumulation of the cyclin-dependent kinase inhibitor p27(Kip1), and inactivation of cyclin-Cdk2 complexes. Time courses demonstrated that 4D5 treatment redirects p27(Kip1) onto Cdk2 complexes, an event preceding increased p27(Kip1) expression; this correlates with the downregulation of c-Myc and D-type cyclins (proteins involved in p27(Kip1) sequestration) and the loss of p27(Kip1) from Cdk4 complexes. Similar events were observed in ErbB2-overexpressing SKBR3 cells, which exhibited reduced proliferation in response to 4D5 treatment. Here, p27(Kip1) redistribution resulted in partial Cdk2 inactivation, consistent with a G1 accumulation. Moreover, p27(Kip1) protein levels remained constant. Antisense-mediated inhibition of p27(Kip1) expression in 4D5-treated BT474 cells further demonstrated that in the absence of p27(Kip1) accumulation, p27(Kip1) redirection onto Cdk2 complexes is sufficient to inactivate Cdk2 and establish the G(1) block. These data suggest that ErbB2 overexpression leads to potentiation of cyclin E-Cdk2 activity through regulation of p27(Kip1) sequestration proteins, thus deregulating the G(1)/S transition. Moreover, through comparison with an ErbB2-overexpressing cell line insensitive to 4D5 treatment, we demonstrate the specificity of these cell cycle events and show that ErbB2 overexpression alone is insufficient to determine the cellular response to receptor inhibition.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760 · cited 3×
“Furthermore, overexpression of ErbB2 correlates with a poor patient prognosis not only in breast cancer (24, 59, 70, 71) but also in other malignancies, such as ovarian (71) and gastric (84) cancers.”
BackgroundStudies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian Cancer
Slamon, D. J., Godolphin, W., Jones, L. A., Holt, J. A., Wong, S. G., Keith, D. E., Levin, W. J., Stuart, S. G., Udove, J., Ullrich, A., et al. (1989) · Science · doi:10.1126/science.2470152 · Cited by 6,816
CDK inhibitors: positive and negative regulators of G1-phase progression
Sherr, C. J., & Roberts, J. M. (1999) · Genes & Development · doi:10.1101/gad.13.12.1501 · Cited by 6,115
Inhibitors of mammalian G1 cyclin-dependent kinases.
Sherr, C. J., & Roberts, J. M. (1995) · Genes & Development · doi:10.1101/gad.9.10.1149 · Cited by 3,243
Cobleigh, M. A., Vogel, C. L., Tripathy, D., Robert, N. J., Scholl, S., Fehrenbacher, L., Wolter, J. M., Paton, V., Shak, S., Lieberman, G., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.9.2639 · Cited by 2,765
Glycogen synthase kinase-3β regulates cyclin D1 proteolysis and subcellular localization
Diehl, J. A., Cheng, M., Roussel, M. F., & Sherr, C. J. (1998) · Genes & Development · doi:10.1101/gad.12.22.3499 · Cited by 2,130
Polyak, K., Lee, M.-H., Erdjument-Bromage, H., Koff, A., Roberts, J. M., Tempst, P., & Massagué, J. (1994) · Cell · doi:10.1016/0092-8674(94)90572-x · Cited by 2,118
Cyclins and cancer II: Cyclin D and CDK inhibitors come of age
Hunter, T., & Pines, J. (1994) · Cell · doi:10.1016/0092-8674(94)90543-6 · Cited by 2,091
p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21
Toyoshima, H., & Hunter, T. (1994) · Cell · doi:10.1016/0092-8674(94)90573-8 · Cited by 2,043
Pagano, M., Tam, S. W., Theodoras, A. M., Beer-Romero, P., Del Sal, G., Chau, V., Yew, P. R., Draetta, G. F., & Rolfe, M. (1995) · Science · doi:10.1126/science.7624798 · Cited by 1,817
Graus-Porta, D. (1997) · The EMBO Journal · doi:10.1093/emboj/16.7.1647 · Cited by 1,590
New functional activities for the p21 family of CDK inhibitors.
LaBaer, J., Garrett, M. D., Stevenson, L. F., Slingerland, J. M., Sandhu, C., Chou, H. S., Fattaey, A., & Harlow, E. (1997) · Genes & Development · doi:10.1101/gad.11.7.847 · Cited by 1,402
Baselga, J., Tripathy, D., Mendelsohn, J., Baughman, S., Benz, C. C., Dantis, L., Sklarin, N. T., Seidman, A. D., Hudis, C. A., Moore, J., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.3.737 · Cited by 1,380
Cheng, M., Olivier, P., Diehl, J. A., Fero, M., Roussel, M. F., Roberts, J. M., & Sherr, C. J. (1999) · The EMBO Journal · doi:10.1093/emboj/18.6.1571 · Cited by 1,142
Pegram, M. D., Lipton, A., Hayes, D. F., Weber, B. L., Baselga, J. M., Tripathy, D., Baly, D., Baughman, S. A., Twaddell, T., Glaspy, J. A., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.8.2659 · Cited by 1,067
Loda, M., Cukor, B., Tam, S. W., Lavin, P., Fiorentinc, M., Draetta, G. F., Jessup, J. M., & Pagano, M. (1997) · Nature Medicine · doi:10.1038/nm0297-231 · Cited by 1,031
Cyclin‐dependent protein kinases: Key regulators of the eukaryotic cell cycle
Nigg, E. A. (1995) · BioEssays · doi:10.1002/bies.950170603 · Cited by 932
Cyclin E-CDK2 is a regulator of p27Kip1.
Sheaff, R. J., Groudine, M., Gordon, M., Roberts, J. M., & Clurman, B. E. (1997) · Genes & Development · doi:10.1101/gad.11.11.1464 · Cited by 911
Porter, P. L., Malone, K. E., Heagerty, P. J., Alexander, G. M., Gatti, L. A., Firpo, E. J., Daling, J. R., & Roberts, J. M. (1997) · Nature Medicine · doi:10.1038/nm0297-222 · Cited by 901
Catzavelos, C., Bhattacharya, N., Ung, Y. C., Wilson, J. A., Roncari, L., Sandhu, C., Shaw, P., Yeger, H., Morava-Protzner, I., Kapusta, L., et al. (1997) · Nature Medicine · doi:10.1038/nm0297-227 · Cited by 823
Specificity within the EGF family/ErbB receptor family signaling network
Riese, D. J., & Stern, D. F. (1998) · BioEssays · doi:10.1002/(sici)1521-1878(199801)20:1<41::aid-bies7>3.0.co;2-v · Cited by 809
Identification of G1 kinase activity for cdk6, a novel cyclin D partner.
Meyerson, M., & Harlow, E. (1994) · Molecular and Cellular Biology · doi:10.1128/mcb.14.3.2077 · Cited by 794
Pinkas-Kramarski, R., Soussan, L., Waterman, H., Levkowitz, G., Alroy, I., Klapper, L., Lavi, S., Seger, R., Ratzkin, B. J., Sela, M., et al. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00603.x · Cited by 769
Hudziak, R. M., Lewis, G. D., Winget, M., Fendly, B. M., Shepard, H. M., & Ullrich, A. (1989) · Molecular and Cellular Biology · doi:10.1128/mcb.9.3.1165 · Cited by 749
Lane, H. A., & Nigg, E. A. (1996) · The Journal of cell biology · doi:10.1083/jcb.135.6.1701 · Cited by 690
Self-citationHunter, T., & Pines, J. (1991) · Cell · doi:10.1016/0092-8674(91)90028-w · Cited by 688
Requirement of p27 Kip1 for Restriction Point Control of the Fibroblast Cell Cycle
Coats, S., Flanagan, W. M., Nourse, J., & Roberts, J. M. (1996) · Science · doi:10.1126/science.272.5263.877 · Cited by 679
ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer.
Karunagaran, D., Tzahar, E., Beerli, R. R., Chen, X., Graus-Porta, D., Ratzkin, B. J., Seger, R., Hynes, N. E., & Yarden, Y. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00356.x · Cited by 674
Self-citationp21-containing cyclin kinases exist in both active and inactive states.
Zhang, H., Hannon, G. J., & Beach, D. (1994) · Genes & Development · doi:10.1101/gad.8.15.1750 · Cited by 632
Berger, M. S., Locher, G. W., Saurer, S., Gullick, W. J., Waterfield, M. D., Groner, B., & Hynes, N. E. (1988) · PubMed · Cited by 611
Self-citationUbiquitination of p27 is regulated by Cdk-dependent phosphorylation and trimeric complex formation
Montagnoli, A., Fiore, F., Eytan, E., Carrano, A. C., Draetta, G. F., Hershko, A., & Pagano, M. (1999) · Genes & Development · doi:10.1101/gad.13.9.1181 · Cited by 597
A neu acquaintance for ErbB3 and ErbB4: A role for receptor heterodimerization in growth signaling
Carraway, K. L., & Cantley, L. C. (1994) · Cell · doi:10.1016/0092-8674(94)90564-9 · Cited by 587
Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas.
Alimandi, M., Romano, A., Curia, M. C., Muraro, R., Fedi, P., Aaronson, S. A., Fiore, P. P. D., & Kraus, M. H. (1995) · PubMed · Cited by 548
Redundant cyclin overexpression and gene amplification in breast cancer cells.
Keyomarsi, K., & Pardee, A. B. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.3.1112 · Cited by 512
Direct induction of cyclin D2 by Myc contributes to cell cycle progression and sequestration of p27
Bouchard, C. (1999) · The EMBO Journal · doi:10.1093/emboj/18.19.5321 · Cited by 502
Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies
Lewis, G. D., Figari, I., Fendly, B., Lee Wong, W., Carter, P., Gorman, C., & Shepard, H. M. (1993) · Cancer Immunology, Immunotherapy · doi:10.1007/bf01518520 · Cited by 498
Myc and Ras collaborate in inducing accumulation of active cyclin E/Cdk2 and E2F
Leone, G., DeGregori, J., Sears, R., Jakoi, L., & Nevins, J. R. (1997) · Nature · doi:10.1038/387422a0 · Cited by 468
Ras Enhances Myc Protein Stability
Sears, R., Leone, G., DeGregori, J., & Nevins, J. R. (1999) · Molecular Cell · doi:10.1016/s1097-2765(00)80308-1 · Cited by 460
Siegel, P. M. (1999) · The EMBO Journal · doi:10.1093/emboj/18.8.2149 · Cited by 442
Press, M. F., Pike, M. C., Chazin, V. R., Hung, G., Udove, J. A., Markowicz, M., Danyluk, J., Godolphin, W. J., Sliwkowski, M. X., & Akita, R. W. (1993) · PubMed · Cited by 426
Prognostic role of the cyclin-dependent kinase inhibitor p27 in non-small cell lung cancer.
Esposito, V., Baldi, A., Luca, A. D., Gröger, A. M., Loda, M. F., Giordano, G. G., Caputi, M., Baldi, F., Pagano, M., & Giordano, A. (1997) · PubMed · Cited by 415
Heregulin‐dependent regulation of HER2/neu oncogenic signaling by heterodimerization with HER3.
Wallasch, C., Weiss, F. U., Niederfellner, G., Jallal, B., Issing, W., & Ullrich, A. (1995) · The EMBO Journal · doi:10.1002/j.1460-2075.1995.tb00101.x · Cited by 406
Yonemura, Y., Ninomiya, I., Yamaguchi, A., Fushida, S., Kimura, H., Ohoyama, S., Miyazaki, I., Endou, Y., Tanaka, M., & Sasaki, T. (1991) · PubMed · Cited by 375
Amati, B. (1998) · Frontiers in Bioscience · doi:10.2741/a239 · Cited by 367
Prigent, S. A., & Gullick, W. J. (1994) · The EMBO Journal · doi:10.1002/j.1460-2075.1994.tb06577.x · Cited by 359
Cyclins D1 and D2 mediate Myc-induced proliferation via sequestration of p27Kip1 and p21Cip1
Perez-Roger, I. (1999) · The EMBO Journal · doi:10.1093/emboj/18.19.5310 · Cited by 329
Gullick, W., Love, S., Wright, C., Barnes, D., Gusterson, B., Harris, A., & Altman, D. (1991) · British Journal of Cancer · doi:10.1038/bjc.1991.100 · Cited by 327
Slingerland, J. M., Hengst, L., Pan, C. H., Alexander, D., Stampfer, M. R., & Reed, S. I. (1994) · Molecular and Cellular Biology · doi:10.1128/mcb.14.6.3683 · Cited by 324
Fukushige, S., Matsubara, K., Yoshida, M., Sasaki, M., Suzuki, T., Semba, K., Toyoshima, K., & Yamamoto, T. (1986) · Molecular and Cellular Biology · doi:10.1128/mcb.6.3.955 · Cited by 324
Growth arrest by the cyclin-dependent kinase inhibitor p27Kip1 is abrogated by c-Myc.
Vlach, J., Hennecke, S., Alevizopoulos, K., Conti, D., & Amati, B. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb01050.x · Cited by 313
Beerli, R. R., & Hynes, N. E. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.11.6071 · Cited by 308
Self-citationGraus-Porta, D., Beerli, R. R., & Hynes, N. E. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.3.1182 · Cited by 296
Self-citationPeng, D., Fan, Z., Yang, L., DeBlasio, T., Scher, H. I., & Mendelsohn, J. M. (1996) · PubMed · Cited by 280
Blain, S. W., Montalvo, E., & Massagué, J. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.41.25863 · Cited by 279
Formation of p27-CDK complexes during the human mitotic cell cycle.
Soos, T. J., Kiyokawa, H., Yan, J. S., Rubin, M. S., Giordano, A., DeBlasio, A., Bottega, S., Wong, B., Mendelsohn, J. M., & Koff, A. (1996) · PubMed · Cited by 274
ErbB-1 and ErbB-2 Acquire Distinct Signaling Properties Dependent upon Their Dimerization Partner
Olayioye, M. A., Graus-Porta, D., Beerli, R. R., Rohrer, J., Gay, B., & Hynes, N. E. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.9.5042 · Cited by 262
Self-citationRB kinases and RB-binding proteins: new points of view
Taya, Y. (1997) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(96)10070-0 · Cited by 257
Identification of a Myc-dependent step during the formation of active G1 cyclin-cdk complexes.
Steiner, P., Philipp, A., Lukas, J., Godden-Kent, D., Pagano, M., Mittnacht, S., Bartek, J., & Eilers, M. (1995) · The EMBO Journal · doi:10.1002/j.1460-2075.1995.tb00163.x · Cited by 246
Mysterious liaisons: the relationship between c-Myc and the cell cycle
Obaya, A. J., Mateyak, M. K., & Sedivy, J. M. (1999) · Oncogene · doi:10.1038/sj.onc.1202749 · Cited by 242
Poon, R. Y., Toyoshima, H., & Hunter, T. (1995) · Molecular Biology of the Cell · doi:10.1091/mbc.6.9.1197 · Cited by 234
Wu, X., Rubin, M., Fan, Z., DeBlasio, T., Soos, T. J., Koff, A., & Mendelsohn, J. M. (1996) · PubMed · Cited by 228
Fedi, P., Pierce, J. H., di Fiore, P. P., & Kraus, M. H. (1994) · Molecular and Cellular Biology · doi:10.1128/mcb.14.1.492 · Cited by 228
Deregulation of cyclin E in breast cancer.
Keyomarsi, K., Conte, D., Toyofuku, W. M., & Fox, M. (1995) · PubMed · Cited by 222
Transformation of NIH 3T3 Cells by HER3 or HER4 Receptors Requires the Presence of HER1 or HER2
Zhang, K., Sun, J., Liu, N., Wen, D., Chang, D., Thomason, A., & Yoshinaga, S. K. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.7.3884 · Cited by 207
Nielsen, N., Arnerlöv, C., Emdin, S. O., & Landberg, G. (1996) · British Journal of Cancer · doi:10.1038/bjc.1996.451 · Cited by 192
Translational induction of the c-myc oncogene via activation of the FRAP/TOR signalling pathway
West, M. J., Stoneley, M., & Willis, A. E. (1998) · Oncogene · doi:10.1038/sj.onc.1201990 · Cited by 183
Beerli, R. R., Graus-Porta, D., Woods-Cook, K., Chen, X., Yarden, Y., & Hynes, N. E. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.12.6496 · Cited by 182
Self-citationMüller, D., Bouchard, C., Rudolph, B., Steiner, P., Stuckmann, I., Saffrich, R., Ansorge, W., Huttner, W., & Eilers, M. (1997) · Oncogene · doi:10.1038/sj.onc.1201440 · Cited by 167
Scott, G. K., Robles, R., Park, J. W., Montgomery, P. A., Daniel, J., Holmes, W. E., Lee, J., Keller, G. A., Li, W. L., & Fendly, B. M. (1993) · Molecular and Cellular Biology · doi:10.1128/mcb.13.4.2247 · Cited by 158
Ye, D., Mendelsohn, J. M., & Fan, Z. (1999) · Oncogene · doi:10.1038/sj.onc.1202319 · Cited by 151
Lewis, G. D., Lofgren, J. A., McMurtrey, A. E., Nuijens, A., FENDLY, B. M., Bauer, K. D., & Sliwkowski, M. X. (1996) · PubMed · Cited by 140
Yasui, W., Kudo, Y., Semba, S., Yokozaki, H., & Tahara, E. (1997) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.1997.tb00428.x · Cited by 139
Orend, G., Hunter, T. R., & Ruoslahti, E. I. (1998) · Oncogene · doi:10.1038/sj.onc.1201791 · Cited by 124
Harwerth, I. M., Wels, W. S., Marte, B. M., & Hynes, N. E. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)42160-6 · Cited by 123
Self-citationA question of balance: the role of cyclin-kinase inhibitors in development and tumorigenesis
Elledge, S. J., Winston, J. T., & Harper, J. W. (1996) · Trends in Cell Biology · doi:10.1016/0962-8924(96)10030-1 · Cited by 120
Berns, K., Hijmans, E. M., & Bernards, R. (1997) · Oncogene · doi:10.1038/sj.onc.1201280 · Cited by 115
Monoclonal antibodies directed to the erbB-2 receptor inhibit in vivo tumour cell growth
Harwerth, I. M., Wels, W. S., Schlegel, J., Müller, M., & Ne, H. (1993) · British Journal of Cancer · doi:10.1038/bjc.1993.494 · Cited by 114
Kumar, R., Shepard, H. M., & Mendelsohn, J. M. (1991) · Molecular and Cellular Biology · doi:10.1128/mcb.11.2.979 · Cited by 111
Marte, B. M., Graus-Porta, D., Jeschke, M. G., Fabbro, D., Hynes, N. E., & Taverna, D. (1995) · PubMed · Cited by 98
Self-citationp185HER2 signal transduction in breast cancer cells
Scott, G. K., Dodson, J. M., Montgomery, P. A., Johnson, R. M., Sarup, J. C., Wong, W., Ullrich, A., Shepard, H. M., & Benz, C. C. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)98683-7 · Cited by 87
Take Your Partners, Please — Signal Diversification by the erbB Family of Receptor Tyrosine Kinases
Daly, R. J. (1999) · Growth Factors · doi:10.3109/08977199909069144 · Cited by 61
Activation of c-Myc uncouples DNA replication from activation of G1-cyclin-dependent kinases
Pusch, O., BERNASCHEK, G., Eilers, M., & Hengstschläger, M. (1997) · Oncogene · doi:10.1038/sj.onc.1201236 · Cited by 60
Lodén, M., Nielsen, N. H., Roos, G., Emdin, S. O., & Landberg, G. (1999) · Oncogene · doi:10.1038/sj.onc.1202488 · Cited by 45
Cited by
ERBB receptors and cancer: the complexity of targeted inhibitors
Hynes, N. E., & Lane, H. A. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1609 · Cited by 3,313
Self-citationA collection of breast cancer cell lines for the study of functionally distinct cancer subtypes
Neve, R. M., Chin, K., Fridlyand, J., Yeh, J., Baehner, F. L., Fevr, T., Clark, L., Bayani, N., Coppe, J.-P., Tong, F., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.10.008 · Cited by 3,188
Self-citationOlayioye, M. A. (2000) · The EMBO Journal · doi:10.1093/emboj/19.13.3159 · Cited by 2,434
The EGF receptor family as targets for cancer therapy
Mendelsohn, J., & Baselga, J. (2000) · Oncogene · doi:10.1038/sj.onc.1204082 · Cited by 1,340
Novel anticancer targets: revisiting ERBB2 and discovering ERBB3
Baselga, J., & Swain, S. M. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2656 · Cited by 1,142
Metadata
- Authors
- Lane, H. A., Beuvink, I., Motoyama, A. B., Daly, J. M., Neve, R. M., & Hynes, N. E.
- Venue
- Molecular and Cellular Biology
- Publisher
- Informa UK Limited
- Published
- 2000-05
- Volume
- 20
- Issue
- 9
- Pages
- 3210-3223
- ISSN
- 0270-7306 (ISSN-L)
- 1098-5549
- OpenAlex
- W2105516763
- Cited by
- 298
- References
- 83
- FWCI
- 11.21
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.